Chugai Pharmaceutical announced plans to construct a new plant for manufacturing antibody active pharmaceutical ingredients (API) at the Ukima Plant (Kita-ku, Tokyo) of Chugai Pharma Manufacturing Co., Ltd., a manufacturing subsidiary of the company.
This new plant for manufacturing antibody active pharmaceutical ingredients (API) capable of high-mix low-volume production for late-stage investigational drugs and initial commercial products at the Ukima Plant. Chugai is aiming to possess global top-class competitiveness by minimizing the time required from the development to launch of a new drug by handling the simultaneous development of multiple products.
With this capital investment, six 6,000 L bioreactor tanks will be newly installed. Combined with the existing two 2,500 L tanks and four 2,000 L tanks, the Ukima Plant will have a total capacity of 49,000 L bioreactor tanks, with a consistent system from process development to production of antibody API of investigational drugs in late-stage clinical studies and initial commercial products at one site.
Overview of Construction Plan of Antibody API Production Plant at Ukima Plant
- • Start of Construction: January 2016
- • Completion of Construction: December, 2017
- • Total Investment: 37.2 billion yen
- • Completion of Building: July, 2018
- • Start of Operation: June, 2019
- • Total Floor Area: 26,634 m2
|Company Name||Chugai Pharmaceutical|
|Type||New Manufacturing Plant|
|Construction Area||4,066 m2|